Impact of Neutropenia on Chemotherapy in Breast Cancer
Author Information
Author(s): Leonard R C F, Miles D, Thomas R, Nussey F
Primary Institution: Cancer Institute Singleton Hospital
Hypothesis
How does neutropenia affect the delivery of planned adjuvant chemotherapy in breast cancer patients?
Conclusion
Neutropenic events significantly impact the ability to deliver planned chemotherapy dose intensity, potentially affecting patient survival.
Supporting Evidence
- 29% of patients experienced at least one neutropenic event.
- Patients with neutropenic events had a significantly lower mean relative dose intensity compared to those without.
- Hospitalization due to febrile neutropenia was recorded in 8% of patients.
Takeaway
When patients with breast cancer get very low white blood cell counts from chemotherapy, it can delay their treatment and make it less effective.
Methodology
Data were collected from 15 UK hospitals on patients starting adjuvant chemotherapy for primary breast cancer, focusing on neutropenic events and their impact on treatment.
Potential Biases
Data collection was retrospective in some centers, which may introduce bias.
Limitations
The audit reflects current clinical practice and is not a controlled clinical trial, which may limit the generalizability of the findings.
Participant Demographics
The median age of participants was 49.3 years, with a majority having Stage II breast cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website